Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection
Abstract Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more broadly, including protecting against viral-associat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Pneumonia |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41479-023-00112-w |
| _version_ | 1797818021359648768 |
|---|---|
| author | Eileen M. Dunne Marta C. Nunes Mary P. E. Slack Christian Theilacker Bradford D. Gessner |
| author_facet | Eileen M. Dunne Marta C. Nunes Mary P. E. Slack Christian Theilacker Bradford D. Gessner |
| author_sort | Eileen M. Dunne |
| collection | DOAJ |
| description | Abstract Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more broadly, including protecting against viral-associated respiratory diseases. In this short narrative review, we highlight clinical studies investigating whether PCVs might have a role in reducing coronavirus disease, both those caused by endemic human coronaviruses (HCoVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). These studies include two randomized controlled trials assessing HCoV-associated pneumonia, one each in children and older adults, and two observational studies of PCV13 effectiveness against HCoV-associated LRTI and COVID-19 in adults. We discuss possible mechanisms for PCV protection including preventing viral pneumococcal co-infections and the possibility that pneumococci in the upper respiratory tract might modify the host immune response to SARS-CoV-2. Lastly, we identify knowledge gaps and further questions on the potential role of PCVs during the COVID-19 pandemic. |
| first_indexed | 2024-03-13T09:02:05Z |
| format | Article |
| id | doaj.art-d9d51b189cf2407abf3b533a48fa2cd9 |
| institution | Directory Open Access Journal |
| issn | 2200-6133 |
| language | English |
| last_indexed | 2024-03-13T09:02:05Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Pneumonia |
| spelling | doaj.art-d9d51b189cf2407abf3b533a48fa2cd92023-05-28T11:18:51ZengBMCPneumonia2200-61332023-05-011511510.1186/s41479-023-00112-wEffects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infectionEileen M. Dunne0Marta C. Nunes1Mary P. E. Slack2Christian Theilacker3Bradford D. Gessner4Pfizer VaccinesCenter of Excellence in Respiratory Pathogens, Hospices Civils de Lyon and Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude BernardSchool of Medicine & Dentistry, Griffith UniversityPfizer VaccinesPfizer VaccinesAbstract Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more broadly, including protecting against viral-associated respiratory diseases. In this short narrative review, we highlight clinical studies investigating whether PCVs might have a role in reducing coronavirus disease, both those caused by endemic human coronaviruses (HCoVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). These studies include two randomized controlled trials assessing HCoV-associated pneumonia, one each in children and older adults, and two observational studies of PCV13 effectiveness against HCoV-associated LRTI and COVID-19 in adults. We discuss possible mechanisms for PCV protection including preventing viral pneumococcal co-infections and the possibility that pneumococci in the upper respiratory tract might modify the host immune response to SARS-CoV-2. Lastly, we identify knowledge gaps and further questions on the potential role of PCVs during the COVID-19 pandemic.https://doi.org/10.1186/s41479-023-00112-wPneumococcal conjugate vaccinesStreptococcus pneumoniaePneumococcusCoronavirusesSARS-CoV-2COVID-19 |
| spellingShingle | Eileen M. Dunne Marta C. Nunes Mary P. E. Slack Christian Theilacker Bradford D. Gessner Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection Pneumonia Pneumococcal conjugate vaccines Streptococcus pneumoniae Pneumococcus Coronaviruses SARS-CoV-2 COVID-19 |
| title | Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| title_full | Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| title_fullStr | Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| title_full_unstemmed | Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| title_short | Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| title_sort | effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection |
| topic | Pneumococcal conjugate vaccines Streptococcus pneumoniae Pneumococcus Coronaviruses SARS-CoV-2 COVID-19 |
| url | https://doi.org/10.1186/s41479-023-00112-w |
| work_keys_str_mv | AT eileenmdunne effectsofpneumococcalconjugatevaccinesonreducingtheriskofrespiratorydiseaseassociatedwithcoronavirusinfection AT martacnunes effectsofpneumococcalconjugatevaccinesonreducingtheriskofrespiratorydiseaseassociatedwithcoronavirusinfection AT marypeslack effectsofpneumococcalconjugatevaccinesonreducingtheriskofrespiratorydiseaseassociatedwithcoronavirusinfection AT christiantheilacker effectsofpneumococcalconjugatevaccinesonreducingtheriskofrespiratorydiseaseassociatedwithcoronavirusinfection AT bradforddgessner effectsofpneumococcalconjugatevaccinesonreducingtheriskofrespiratorydiseaseassociatedwithcoronavirusinfection |